Abstract

Classification criteria for antiphospholipid syndrome have not been updated since the revised Sapporo classification criteria were published in 2006. These criteria have limitations in that they omit nonclassical manifestations (hematologic and neurologic), include anticardiolipin and anti–β2-glycoprotein I immunoglobulin (Ig)M isotypes, and do not separately consider primary (no autoimmune disease) or secondary (usually systemic lupus erythematosus) disease. Recent findings in antiphospholipid antibody include fluctuation of antiphospholipid antibodies, recognition that IgA isotypes do confer risk, identification of the role of complementopathy in catastrophic antiphospholipid syndrome, and elucidation of the role of thrombosis risk equations.

References

References
1.
Somers
E
,
Magder
LS
,
Petri
M
.
Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus
.
J Rheumatol
.
2002
;
29
(
12
):
2531
-
2536
.
2.
Miyakis
S
,
Lockshin
MD
,
Atsumi
T
, et al
.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
.
J Thromb Haemost
.
2006
;
4
(
2
):
295
-
306
.
3.
Domingues
V
,
Magder
LS
,
Petri
M
.
Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE
.
Lupus Sci Med
.
2016
;
3
(
1
):
e000107
.
4.
Yelnik
CM
,
Laskin
CA
,
Porter
TF
, et al
.
Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results
.
Lupus Sci Med
.
2016
;
3
(
1
):
e000131
.
5.
Chayoua
W
,
Kelchtermans
H
,
Moore
GW
, et al
.
Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays
.
J Thromb Haemost
.
2018
;
16
(
10
):
2016
-
2023
.
6.
Mehrani
T
,
Petri
M
.
Association of IgA anti-β2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus
.
J Rheumatol
.
2011
;
38
(
1
):
64
-
68
.
7.
Akhter
E
,
Shums
Z
,
Norman
GL
,
Binder
W
,
Fang
H
,
Petri
M
.
Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus
.
J Rheumatol
.
2013
;
40
(
3
):
282
-
286
.
8.
Pericleous
C
,
Ferreira
I
,
Borghi
O
, et al
.
Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome
.
PLoS One
.
2016
;
11
(
6
):
e0156407
.
9.
Tebo
AE
,
Willis
R
,
Jaskowski
TD
, et al
.
Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus
.
Clin Chim Acta
.
2016
;
460
:
107
-
113
.
10.
Petri
M
,
Orbai
AM
,
Alarcón
GS
, et al
.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
.
Arthritis Rheum
.
2012
;
64
(
8
):
2677
-
2686
.
11.
Antovic
A
,
Norberg
EM
,
Berndtsson
M
, et al
.
Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting
.
Thromb Haemost
.
2017
;
117
(
9
):
1700
-
1704
.
12.
Shi
H
,
Zheng
H
,
Yin
YF
, et al
.
Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome
.
Clin Chem Lab Med
.
2018
;
56
(
4
):
614
-
624
.
13.
Meroni
PL
.
Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools
.
Lupus
.
2016
;
25
(
8
):
905
-
910
.
14.
Liestøl
S
,
Sandset
PM
,
Mowinckel
MC
,
Wisløff
F
.
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants
.
J Thromb Haemost
.
2007
;
5
(
11
):
2204
-
2211
.
15.
Mehta
BM
,
Kiani
AN
,
Chen
C
,
Jani
J
,
Kickler
TS
,
Petri
M
.
Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus
.
Am J Hematol
.
2010
;
85
(
1
):
83
-
85
.
16.
Rand
JH
,
Wu
XX
,
Quinn
AS
,
Taatjes
DJ
.
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis
.
Lupus
.
2010
;
19
(
4
):
460
-
469
.
17.
Brodsky
RA
.
Complement in hemolytic anemia
.
Blood
.
2015
;
126
(
22
):
2459
-
2465
.
18.
Keragala
CB
,
Draxler
DF
,
McQuilten
ZK
,
Medcalf
RL
.
Haemostasis and innate immunity - a complementary relationship: a review of the intricate relationship between coagulation and complement pathways
.
Br J Haematol
.
2018
;
180
(
6
):
782
-
798
.
19.
Girardi
G
,
Redecha
P
,
Salmon
JE
.
Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation
.
Nat Med
.
2004
;
10
(
11
):
1222
-
1226
.
20.
Vaught
AJ
,
Braunstein
EM
,
Jasem
J
, et al
.
Germline mutations in the alternative pathway of complement predispose to HELLP syndrome
.
JCI Insight
.
2018
;
3
(
6
):
99128
.
21.
Fakhouri
F
,
Jablonski
M
,
Lepercq
J
, et al
.
Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome
.
Blood
.
2008
;
112
(
12
):
4542
-
4545
.
22.
Crovetto
F
,
Borsa
N
,
Acaia
B
, et al
.
The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome
.
J Matern Fetal Neonatal Med
.
2012
;
25
(
11
):
2322
-
2325
.
23.
Vaught
AJ
,
Gavriilaki
E
,
Hueppchen
N
, et al
.
Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome
.
Exp Hematol
.
2016
;
44
(
5
):
390
-
398
.
24.
Shanmugalingam
R
,
Hsu
D
,
Makris
A
.
Pregnancy-induced atypical haemolytic uremic syndrome: a new era with eculizumab
.
Obstet Med
.
2018
;
11
(
1
):
28
-
31
.
25.
Burwick
RM
,
Feinberg
BB
.
Eculizumab for the treatment of preeclampsia/HELLP syndrome
.
Placenta
.
2013
;
34
(
2
):
201
-
203
.
26.
Alrahmani
L
,
Willrich
MAV
.
The complement alternative pathway and preeclampsia
.
Curr Hypertens Rep
.
2018
;
20
(
5
):
40
.
27.
Kim
MY
,
Guerra
MM
,
Kaplowitz
E
, et al
.
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies
.
Ann Rheum Dis
.
2018
;
77
(
4
):
549
-
555
.
28.
Thurman
JM
,
Kraus
DM
,
Girardi
G
, et al
.
A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice
.
Mol Immunol
.
2005
;
42
(
1
):
87
-
97
.
29.
Holers
VM
,
Girardi
G
,
Mo
L
, et al
.
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss
.
J Exp Med
.
2002
;
195
(
2
):
211
-
220
.
30.
Girardi
G
,
Berman
J
,
Redecha
P
, et al
.
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
.
J Clin Invest
.
2003
;
112
(
11
):
1644
-
1654
.
31.
Pierangeli
SS
,
Girardi
G
,
Vega-Ostertag
M
,
Liu
X
,
Espinola
RG
,
Salmon
J
.
Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia
.
Arthritis Rheum
.
2005
;
52
(
7
):
2120
-
2124
.
32.
Fischetti
F
,
Durigutto
P
,
Pellis
V
, et al
.
Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor
.
Blood
.
2005
;
106
(
7
):
2340
-
2346
.
33.
Meroni
PL
,
Macor
P
,
Durigutto
P
, et al
.
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery
.
Blood
.
2016
;
127
(
3
):
365
-
367
.
34.
Asherson
RA
,
Cervera
R
,
Piette
JC
, et al
.
Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients
.
Medicine (Baltimore)
.
1998
;
77
(
3
):
195
-
207
.
35.
Asherson
RA
,
Cervera
R
,
de Groot
PG
, et al
;
Catastrophic Antiphospholipid Syndrome Registry Project Group
.
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines
.
Lupus
.
2003
;
12
(
7
):
530
-
534
.
36.
Cervera
R
,
Rodríguez-Pintó
I
,
Espinosa
G
.
The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review
.
J Autoimmun
.
2018
;
92
:
1
-
11
.
37.
Mustonen
P
,
Lehtonen
KV
,
Javela
K
,
Puurunen
M
.
Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study
.
Lupus
.
2014
;
23
(
14
):
1468
-
1476
.
38.
Pengo
V
,
Ruffatti
A
,
Legnani
C
, et al
.
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
.
Blood
.
2011
;
118
(
17
):
4714
-
4718
.
39.
Otomo
K
,
Atsumi
T
,
Amengual
O
, et al
.
Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events
.
Arthritis Rheum
.
2012
;
64
(
2
):
504
-
512
.
40.
Sciascia
S
,
Sanna
G
,
Murru
V
,
Roccatello
D
,
Khamashta
MA
,
Bertolaccini
ML
.
GAPSS: the Global Anti-Phospholipid Syndrome Score
.
Rheumatology (Oxford)
.
2013
;
52
(
8
):
1397
-
1403
.
41.
Sciascia
S
,
Radin
M
,
Sanna
G
,
Cecchi
I
,
Roccatello
D
,
Bertolaccini
ML
.
Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis
.
Rheumatology (Oxford)
.
2018
;
57
(
4
):
661
-
665
.
42.
Sciascia
S
,
Cuadrado
MJ
,
Sanna
G
, et al
.
Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort
.
Arthritis Care Res (Hoboken)
.
2014
;
66
(
12
):
1915
-
1920
.
43.
Zuily
S
,
de Laat
B
,
Mohamed
S
, et al
;
TAC(I)T investigators
.
Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study
.
Rheumatology (Oxford)
.
2015
;
54
(
11
):
2071
-
2075
.
44.
Oku
K
,
Amengual
O
,
Bohgaki
T
,
Horita
T
,
Yasuda
S
,
Atsumi
T
.
An independent validation of the Global Anti-Phospholipid Syndrome Score in a Japanese cohort of patients with autoimmune diseases
.
Lupus
.
2015
;
24
(
7
):
774
-
775
.
45.
Petri
M
,
Rheinschmidt
M
,
Whiting-O’Keefe
Q
,
Hellmann
D
,
Corash
L
.
The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level
.
Ann Intern Med
.
1987
;
106
(
4
):
524
-
531
.
46.
Galli
M
,
Luciani
D
,
Bertolini
G
,
Barbui
T
.
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
.
Blood
.
2003
;
101
(
5
):
1827
-
1832
.
47.
Baroni
G
,
Banzato
A
,
Bison
E
,
Denas
G
,
Zoppellaro
G
,
Pengo
V
.
The role of platelets in antiphospholipid syndrome
.
Platelets
.
2017
;
28
(
8
):
762
-
766
.
48.
Hollerbach
A
,
Müller-Calleja
N
,
Ritter
S
, et al
.
Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors
.
Thromb Haemost
.
2019
;
119
(
7
):
1147
-
1153
.
49.
Hisada
R
,
Kato
M
,
Sugawara
E
, et al
.
Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study
.
J Thromb Haemost
.
2017
;
15
(
9
):
1782
-
1787
.
50.
Navratil
JS
,
Manzi
S
,
Kao
AH
, et al
.
Platelet C4d is highly specific for systemic lupus erythematosus
.
Arthritis Rheum
.
2006
;
54
(
2
):
670
-
674
.
51.
Kao
AH
,
McBurney
CA
,
Sattar
A
, et al
.
Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus
.
Transl Stroke Res
.
2014
;
5
(
4
):
510
-
518
.
52.
Merrill
JT
,
Petri
MA
,
Buyon
J
, et al
.
Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
.
Lupus Sci Med
.
2018
;
5
(
1
):
e000263
.
53.
Mehta
N
,
Uchino
K
,
Fakhran
S
, et al
.
Platelet C4d is associated with acute ischemic stroke and stroke severity
.
Stroke
.
2008
;
39
(
12
):
3236
-
3241
.
54.
Lonati
PA
,
Scavone
M
,
Gerosa
M
, et al
.
Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome
.
Front Immunol
.
2019
;
10
:
773
.
You do not currently have access to this content.